Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease

Chinese Medical Journal

Volumn 119, Issue 22, 2006, Pages 1871-1876

  Hu, Rong ^a   Ma, Chang Sheng ^a   Nie, Shao Ping ^a   Lü, Qiang ^a   Kang, Jun Ping ^a   Du, Xin ^a   Zhang, Yin ^a   Gao, Ying Chun ^a   He, Li Qun ^a   Jia, Chang Qi ^a   Liu, Xin Min ^a   Dong, Jian Zeng ^a   Liu, Xiao Hui ^a   Chen, Fang ^a   Zhou, Yu Jie ^a   Lü, Shu Zheng ^a   Wu, Xue Si ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Coronary artery disease; Metabolic syndrome; Revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; COST OF ILLNESS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROGNOSIS; REGISTER; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33751401386     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200611020-00005     Document Type: Article

References (20)

1. Scott CI. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003: 92: 35i-42i.
2. WU GX. The prevalence of metabolic syndrome in a 11 provinces cohorts in China. Chin J Prev Med (Chin) 2002; 36: 298-305.
3. Lakka HM, Laaksonca DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
4. Lu YH, Lu JM, Wang SY, Li CL, Liu LS, Zheng RM, et al. Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that Chinese Medical Association Diabetes Branch. Natl Med J Chin (Chin) 2006; 86: 386-389.
5. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - anew worldwide definition. Lancet 2005; 366: 1059-1062.
6. Gazzaruso C, Solerte SB, De Amici E, Mancini M, Pujia A, Fratino P, et al. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: 236-239.
7. Lin RT, Lee WJ, Jeng CY, Sheu WH, Chen YT. Metabolic syndrome and its contribution to coronary artery disease in non-diabetic subjects. J Formos Med Assoc 2004; 103: 317-320
8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
9. Birhan Yilamz M, Guray Y, Altay H, Demirkan B, Caldir V, Cay S, et al. Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron Atery Dis 2005; 16: 287-292.
10. Baltali M, Gokcel A, Kiziltan HT, Korkmaz ME, Topcu S, Yalcin F, et al. Association between the metabolic syndrome and newly diagnosed coronary artery disease. Diabetes Nur Metab 2003; 16: 169-175.
11. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitecomb B, et al. The metabolic syndrome, diabetes and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 2003; 41: 1547-1553.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular event: an 8-year followup of 14 719 initially health American woman. Circulation 2003; 107: 391-397.
13. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcilm M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atheroscierotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93:159-164.
14. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21: 252-255.
15. Cankurtaran M, Halil M, Yavuz BB, Dagli N, Oyan B, Ariogul S. Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr 2006; 42: 35-45.
16. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004; 101: 185-193.
17. Fisman EZ, Motro M, Tenenbaum A. Impaired fasting glucose concentration in nondiabetics with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001; 141: 485-490.
18. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently assiociated with premature familial coronary artery disease. J Am Coll Cardiol 2005; 45: 1003-1012.
19. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-2607.
20. Cziraky MY. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc (Wash DC) 2004; 44: 478-488.